101
|
Yuan T, Wang XY, Lai YY, Qin YZ, Shi HX, Huang XJ, Jiang Q. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:547-553. [PMID: 32397016 PMCID: PMC7364897 DOI: 10.3760/cma.j.issn.0253-2727.2019.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Indexed: 02/03/2023]
Abstract
Objective: To compare the clinical features between the 2 cohorts developing myelodysplastic syndrome or acute myeIogenous Ieukemia in Philadelphia chromosome-negative cells (Ph(-) MDS/AML) and maintaining disease stable in the patients with Philadelphia chromosome-positive chronic myeloid Ieukemia (Ph(+) CML) who had clonal chromosomal abnormalities in Philadelphia chromosome-negative metaphases (CCA/Ph(-)) during tyrosine kinase inhibtor (TKI) - therapy. Methods: We retrospectively analyzed Ph(+) CML patients who developed CCA/Ph(-) during TKI-therapy from May 2001 to December 2017. Results: Data of CCA/Ph(-) 63 patients, including 7 progressing to Ph(-) MDS/AML and 56 remaining disease stable were collected. Compared with those with stable disease, patients with Ph(-)MDS/AML had lower hemoglobin (P=0.007) and platelet (P=0.006) counts, and higher proportion of peripheral blasts (P<0.001) when the first time CCA/Ph(-) was detected, and more mosonomy 7 abnormality (5/7, 71.4%) when MDS or AML was diagnosed; meanwhile, trisomy 8 (32/56, 57.1%) was more common in those with stable disease. Outcome of the patients with Ph(-) MDS/AML were poor. However, most of those with CCA/Ph(-) and stable disease had optimal response on TKI-therapy. Conclusions: A few patients with Ph(+) CML developed CCA/Ph(-) during TKI-therapy, most of them had stable disease, but very few patients developed Ph(-) MDS/AML with more common occurrence of monosomy 7 or unknown cytopenia. Our data suggested the significance of monitoring of peripheral blood smear, bone marrow morphology and cytogenetic analysis once monosomy 7 or unknown cytopenia occurred.
Collapse
MESH Headings
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/drug therapy
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative/physiopathology
- Philadelphia Chromosome
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Retrospective Studies
Collapse
|
102
|
Sun YQ, Huang XJ. [Invasive fungal disease: the old question and new confusion to Chinese physician]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:537-540. [PMID: 32397014 PMCID: PMC7364906 DOI: 10.3760/cma.j.issn.0253-2727.2019.07.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/17/2019] [Indexed: 01/06/2023]
|
103
|
Suo P, Cheng YF, Huang XJ. [Vaccination of hematopoietic stem cell transplantation patients]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:344-347. [PMID: 31104452 PMCID: PMC7343013 DOI: 10.3760/cma.j.issn.0253-2727.2019.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
104
|
Lin CH, Li PH, Yang M, Ye JJ, Huang XJ. Metal Replacement Causing Interference in Stripping Analysis of Multiple Heavy Metal Analytes: Kinetic Study on Cd(II) and Cu(II) Electroanalysis via Experiment and Simulation. Anal Chem 2019; 91:9978-9985. [PMID: 31246003 DOI: 10.1021/acs.analchem.9b01724] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Although it has been recognized that the interference between heavy metal ions (HMIs) becomes a severe problem for the simultaneous electroanalysis of multiple HMIs, the factor leading to the interference is still difficult to identify, due to the limited understanding of the electroanalytic kinetics. In this work, a kinetic model is built for the electroanalysis of HMIs, and the electroanalytic results are simulated for Cd(II), Cu(II), and their mixture as examples for the interference investigation. The mutual interference between Cd and Cu is observed on the glassy carbon electrode. By applying the kinetic model, the replacement of deposited Cd by Cu(II) at the codeposition stage is regarded as the main reason for the interference, and the corresponding suggestion for selecting suitable electrode materials to avoid such interference is also provided.
Collapse
|
105
|
Jia JS, Zhu HH, Gong LZ, Zhao T, Wang J, Jiang Q, Huang XJ, Jiang H. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:398-403. [PMID: 31207705 PMCID: PMC7342235 DOI: 10.3760/cma.j.issn.0253-2727.2019.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the efficacy and prognostic factors of induction therapy in FLT3-ITD(+) acute myeloid leukemia (AML) in the real world data. Methods: From January 2013 to December 2016, 114 de novo patients with FLT3-ITD(+)AML were enrolled in this study. Out of 114 cases, 75 were male, and 39 were female. The median age was 42 years old (ranged from 14 to 72 years old) . The chemotherapy regimens were used for induction therapy and all cases were followed up. The treatment response was evaluated by MICM and the comparison of the ratio were analyzed by chi-square test and the survival was estimated by Kaplan-Meier analysis and Cox proportional hazards model was used to identify independent prognostic factors. Results: There were 52 FLT3-ITD(+)AML patients with favorable prognosis genes (46 cases with NPM1, 5 cases with RUNX1-RUNX1T1, 1 case with CEBPA double mutation) and 62 patients with other types of FLT3-ITD(+)AML at diagnosis. All patients completed at least one cycle of induction therapy and the clinical curative effect was evaluated, complete remission (CR) rate was 50.0% (57/114) in one cycle and total CR rate was 72.5% (74/104) in two cycles. The CR rate of the FLT3-ITD(+) AML patients with favorable prognosis genes was 67.3% (35/52) in one cycle and 83.3% (40/48) in two cycles; for the other types FLT3-ITD(+)AML patients, the CR rate was 35.5% (22/62) in one cycle and 64.8% (35/54) in two cycles. There was a significant difference in CR rate between the FLT3-ITD(+)AML patients with and without favorable prognosis genes (P<0.05) . This indicates that the FLT3-ITD(+)AML patients with favorable prognosis gene had relatively good therapeutic effect. Among other types of FLT3-ITD(+)AML patients who did not achieve remission from one cycle of chemotherapy, 9 patients were given sorafenib plus chemotherapy and 6 cases (66.7%) achieved CR; 23 patients were given conventional chemotherapy and 7 cases (30.4%) achieved CR. There was a significant difference between sorafenib plus chemotherapy and conventional chemotherapy groups (χ(2)=4.47, P<0.05) and this indicates that sorafenib plus chemotherapy can significantly improve the CR rate of FLT3-ITD(+)AML patients. Comparing overall survival (OS) and disease free survival (DFS) , there was no significant difference between sorafenib plus chemotherapy and conventional chemotherapy groups (P values were 0.641 and 0.517, respectively) . Conclusion: The overall prognosis of FLT3-ITD(+)AML patients is poor, and the stratification therapeutic efficacy of FLT3-ITD(+)AML without favorable prognosis gene can be improved by sorafenib combined with chemotherapy.
Collapse
|
106
|
Sun YF, Sun JH, Wang J, Pi ZX, Wang LC, Yang M, Huang XJ. Sensitive and anti-interference stripping voltammetry analysis of Pb(II) in water using flower-like MoS2/rGO composite with ultra-thin nanosheets. Anal Chim Acta 2019; 1063:64-74. [DOI: 10.1016/j.aca.2019.03.008] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Revised: 03/05/2019] [Accepted: 03/06/2019] [Indexed: 12/14/2022]
|
107
|
Chen Y, Zhang XH, Xu LP, Liu KY, Qin J, Yang YL, Huang XJ. [Haploidentical allogenetic hematopoietic stem cell transplantation for X-linked adrenoleukodystrophy]. JOURNAL OF PEKING UNIVERSITY. HEALTH SCIENCES 2019; 51:409-413. [PMID: 31209410 DOI: 10.19723/j.issn.1671-167x.2019.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE X-linked adrenoleukodystrophy (ALD) is a severe inherited disorder leading to rapid neurological deterioration and premature death. Allogeneic hematopoietic stem cell transplantation (HSCT) is still the only treatment that halts the neurologic symptoms in ALD. However, many patients lack suitable human leukocyte antigen (HLA) matched related donors and must rely on alternative donors for a source of stem cells. The purpose of this study was to explore the outcomes of haploidentical allogeneic stem cell transplantation for ALD patients. METHODS Between December 2014 and December 2018, eight children with ALD lacking HLA matched related or unrelated donors were treated with haploidentical allogeneic hematopoietic stem cell transplantation. The patients received conditioning regimen with busulfan 9.6 mg/kg, cyclophosphamide 200 mg/kg and fludarabine 90 mg/m2. Graft-versus-host disease (GVHD) prophylaxis consisted of anti-human thymocyte globulin, cyclosporine A, mycophenolate mofetil and short course of methotrexate. RESULTS All the 8 children received allogeneic stem cell transplants from their fathers. The median age of the recipients was 8 (range: 5-12) years. The median age of the donors was 36 (range: 32-40) years. All the recipients received granulocyte colony-stimulating factor (G-CSF) mobilized bone marrow and peripheral blood-derived stem cells. The median number of total mononuclear cells dose and CD34+ dose was 10.89 (range: 9.40-12.16)×108/kg and 7.06 (range: 0.74-7.80)×106/kg, respectively. Neutrophil engraftment occurred a median of 11 days (range:8-13 days) after transplantation. Platelet engraftment occurred a median of 10 days (range:8-12 days) after transplantation. All the patients achieved complete donor chimerism at the time of engraftment. Four patients had grades II-IV acute GVHD and 1 had chronic graft-versus-host disease. No severe chronic GVHD occurred. Among all the children, 2 had cytomegalovirus (CMV) DNAemia and 2 Epstein-Barr virus (EBV) DNAemia. Overall, seven of them survived and had no major complications related to transplantation. One died of cerebral hernia after epilepsy 125 days after transplantation. CONCLUSION The preliminary observation demonstrates that haploidentical allogeneic stem cell transplantation with this novel regimen could successfully achieve full donor chimerism in ALD patients. According to our experience, haploidentical allogeneic hematopoietic stem cell transplantation is safe and feasible in the treatment of X-linked adrenoleukodystrophy.
Collapse
|
108
|
Yu L, Qin YZ, Lai YY, Shi HX, Huang XJ, Jiang Q. [Severe hematologic toxicity and its impact on treatment response in newly diagnosed patients with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:281-287. [PMID: 31104438 PMCID: PMC7343016 DOI: 10.3760/cma.j.issn.0253-2727.2019.04.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 评估慢性髓性白血病(CML)初诊患者酪氨酸激酶抑制剂(TKI)一线治疗中严重的白细胞和(或)血小板减少的发生率、相关因素及其对治疗反应及生存的影响。 方法 回顾性分析2001年1月至2018年1月诊治的初诊CML慢性期(CP)或加速期(AP)连续病例资料。 结果 共收集855例患者的数据,其中523例(61.2%)为男性,中位年龄39(14~87)岁。CP患者744例(87.0%),AP患者111例(13.0%)。一线服用伊马替尼749例(87.6%),尼洛替尼93例(10.9%),达沙替尼13例(1.5%)。137例(16.0%)在中位1.0(0.1~7.0)个月时发生≥3级白细胞和(或)血小板减少,持续0.6(0.3~6.5)个月。多因素分析显示,女性(OR=1.5,95%CI 1.0~2.2,P=0.033)、诊断时WBC ≥100×109/L(OR=1.9,95%CI 1.3~2.8,P=0.001)、CP-Sokal高危(OR=2.2,95%CI 1.2~3.9,P=0.005)和原始细胞增多型AP(OR=5.1,95%CI 1.9~13.3,P=0.001)与≥3级白细胞和(或)血小板减少的发生显著相关。与未发生≥3级白细胞和(或)血小板减少相比,发生≥3级白细胞和(或)血小板减少且停药>2周与较低的完全细胞遗传学反应率(OR=0.4,95%CI 0.3~0.6,P<0.001)显著相关;发生≥3级白细胞和(或)血小板减少,无论停药是否>2周,均与较低的主要分子学反应率(OR=0.3,95%CI 0.2~0.5,P<0.001;OR=0.7,95%CI 0.5~1.0,P=0.036)和MR4.5率(OR=0.2,95%CI 0.1~0.5,P=0.002;OR=0.7,95%CI 0.4~1.1,P=0.110)相关,但不影响疾病进展和生存。 结论 严重的白细胞和(或)血小板减少是TKI治疗中常见的不良反应,女性、诊断时WBC ≥100×109/L和CP-Sokal高危、原始细胞增多型AP是严重的白细胞和(或)血小板减少发生的高危人群。发生严重的白细胞和(或)血小板减少降低了TKI治疗中的细胞遗传学和分子学反应率。
Collapse
|
109
|
Shi HY, Cheng YF, Huang XJ, Wang Y, Suo P, Xu LP, Liu KY, Zhang XH, Yan CH, Wang FR, Sun YQ, Zhang S, Kong J, Gao YQ, Xie YX. [Clinical analysis of cytomegalovirus infection after haplotype hematopoietic stem cell transplantation in children]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:426-428. [PMID: 31207710 PMCID: PMC7342226 DOI: 10.3760/cma.j.issn.0253-2727.2019.05.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Indexed: 11/13/2022]
|
110
|
Qin YZ, Huang XJ. [Application and challenges of the new generation detection technologies in precision medicine for leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 40:353-357. [PMID: 31207696 PMCID: PMC7342227 DOI: 10.3760/cma.j.issn.0253-2727.2019.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Indexed: 11/05/2022]
|
111
|
Xie YX, Wang Y, Huang XJ, Xu LP, Zhang XH, Liu KY, Yan CH, Wang FR, Sun YQ, Kong J, Gao YQ, Shi HY, Liu DP, Cheng YF. [Clinical analysis of hemorrhagic cystitis in children and adolescents with hematological diseases post haplo-hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:833-838. [PMID: 30369205 PMCID: PMC7348279 DOI: 10.3760/cma.j.issn.0253-2727.2018.10.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
目的 观察儿童及青少年血液病患者单倍型造血干细胞移植(haplo-HSCT)后出血性膀胱炎(HC)的临床特征并探讨其影响因素。 方法 回顾性分析2015至2016年接受haplo-HSCT的89例儿童及青少年血液病患者的临床资料。 结果 全部89例患者中,≤14岁62例(儿童组)、>14~<18岁27例(青少年组);男56例,女33例;中位移植年龄10(1~17)岁;急性淋巴细胞白血病(ALL)44例,急性髓系白血病(AML)33例,急性混合细胞白血病(AHL)3例,骨髓增生异常综合征(MDS)9例。移植物来源均为骨髓+外周血干细胞。全部89例患者中32例(36%)发生HC,其中迟发型31例,早发型1例;Ⅰ度6例、Ⅱ度16例、Ⅲ度8例、Ⅳ度2例;HC发病中位时间为移植后25(2~55)d,中位持续时间为19(3~95)d;所有患儿均获得治愈。儿童组HC发病率低于青少年组[27.4%(17/62)对55.6%(15/27),χ2=6.466,P<0.05]。儿童组中<5岁组HC发生率低于5~14岁组[0(0/12)对34%(17/50),χ2=4.043,P<0.05]。 结论 HC是儿童及青少年血液病患者haplo-HSCT的常见并发症,总体预后良好,年龄是其发生的影响因素。
Collapse
|
112
|
Liu J, Liu YR, Wang YZ, Han W, Chen H, Chen Y, Wang JZ, Mo XD, Zhang YY, Yan CH, Sun YQ, Chen YY, Wang Y, Xu LP, Zhang XH, Liu KY, Huang XJ, Chang YJ. [The comparison of predicting clinical outcomes between immunolophenotype and hematological complete remission before human leukocyte antigen-matched sibling donor transplantation in acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:617-623. [PMID: 30180459 PMCID: PMC7342848 DOI: 10.3760/cma.j.issn.0253-2727.2018.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
目的 比较移植前免疫表型缓解(ICR)和血液形态学缓解对急性髓系白血病(AML)患者同胞HLA相合造血干细胞移植(MSDT)疗效的预测价值。 方法 回顾性分析182例接受MSDT的AML患者(除外急性早幼粒细胞白血病),将移植前血液形态学缓解分为血细胞恢复的完全缓解(CR)、血小板未恢复的CR(CRp)、血小板和中性粒细胞均未恢复的CR(CRi),将多参数流式细胞术检测微小残留病阴性定义为ICR。 结果 ①全部182例AML患者中,男97例,女85例,中位年龄41(4~62)岁。②移植前CR、CRp+CRi率分别为80.8%(147/182)、19.2%(35/182);移植前CRp+CRi组、CR组的预期4年累积复发率(CIR)[(11.0±4.3)%对(16.0±7.1)%,χ2=0.274,P=0.600]、非复发死亡率(NRM)[(14.0±4.3)%对(9.0±6.3)%,χ2=0.913,P=0.339]、无白血病生存(LFS)率[(75.0±5.1)%对(75.0±8.3)%,χ2=0.256,P=0.613]、总生存(OS)率[(77.0±5.2)%对(80.0±8.1)%,χ2=0.140,P=0.708]差异均无统计学意义。③移植前ICR组(147例)与非ICR组(35例)比较,4年CIR较低[(11.3±3.4)%对(55.2±8.8)%,χ2=32.687,P<0.001],LFS率[(76.2±4.7)%对(32.8±8.7)%,χ2=26.234,P<0.001]和OS率[(79.0±4.7)%对(39.0±9.1)%,χ2=25.253,P<0.001]较高,NRM差异无统计学意义[(12.5±4.1)%对(12.0±7.1)%,χ2=1.002,P=0.656]。④多因素分析显示,移植前非ICR是影响AML患者MSDT后复发[HR=11.026(95% CI 4.685~25.949),P<0.001]、LFS[HR=5.785(95% CI 2.974~11.254),P< 0.001]和OS[HR=5.578(95%CI 2.575~27.565),P<0.001]的独立危险因素。 结论 移植前ICR对AML患者MSDT的疗效预测价值优于HCR。
Collapse
|
113
|
Sun YQ, Huang XJ, Xu LP, Zhang XH, Yan CH, Liu KY, Wang Y. [Impact of mycophenolate mofetil prophylaxis duration on acute graft-versus-host disease after haploidentical stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:286-291. [PMID: 29779322 PMCID: PMC7342124 DOI: 10.3760/cma.j.issn.0253-2727.2018.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the impact of mycophenolate mofetil (MMF) prophylaxis duration on acute graft-versus-host disease (aGVHD) after haploidentical stem cell transplantation (haplo-HSCT) using 'Beijing Protocol'. Methods: Adult patients (≥14 years) received haplo-HSCT in Peking University Institute of Hematology from Sep, 2016 to Mar, 2017 were retrospectively reviewed if they fulfilled the criterias: ①diagnosed with hematological maligancies; ②standard-risk status at haplo-HSCT. A total of 237 patients [including 102 patients with long MMF duration (defined as started on day -9 with 100 mg/d, adjusted to 500 mg/d from day +30 and discontinued on day +45 to +60 or occurrence of CMV/EBV reactivation or late-onset hemorrhagic cytitis), and 135 patients with short MMF duration (defined as started on day -9 with 500 mg/d and discontinued on the day achieved neutrophil engraftment)] were reviewed. The incidence of aGVHD, virus infection and overall survival (OS) were compared between the two groups. Results: The median durations of MMF prophylaxis of long and short duration groups were 27(7-71) and 15(9-24) days, respectively after haplo-HSCT. There were no differences of baseline characteristics (including sex, patient age, disease, mismatched HLA loci, donor-recipient relation, donor-recipient sex and donor age) between the two groups. The incidences of the grade Ⅱ-Ⅳ and Ⅲ/Ⅳ aGVHD in long and short duration groups were 31.1% versus 17.6% (P=0.018) and 7.4% verus 7.8% (P=0.900), respectively. The duration of MMF prophylaxis was not found to be associated with gradeⅡ-Ⅳ aGVHD by the multivariate analysis. There were no significant differences in terms of CMV viremia, EBV viremia, hemorrhagic cytitis and OS between the two groups. Conclusion: Prophylaxis with short duration MMF in the setting of 'Beijing protocol' haplo-SCT was not associated with increased acute GVHD with no impact on OS, which indicated that short duration MMF might be a feasible GVHD prophylaxis regimen.
Collapse
|
114
|
Fei Q, Huang XJ, Liu Y, Xu LP, Zhang XH, Liu KY, Chen H, Chen YY, Wang Y. [The clinical analysis of haploidentical stem cell transplantation in myelodysplastic syndrome-associated acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:546-551. [PMID: 30122012 PMCID: PMC7342220 DOI: 10.3760/cma.j.issn.0253-2727.2018.07.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
目的 探讨单倍型造血干细胞移植(haplo-HSCT)治疗伴骨髓增生异常综合征相关特征急性髓系白血病(AML-MRC)的预后。 方法 回顾性分析2009年1月至2015年7月在北京大学人民医院接受haplo-HSCT的102例第1次完全缓解期(CR1)高危AML患者的临床资料。 结果 全部102例AML患者中,AML-MRC 17例(AML-MRC组),其他类型AML 85例(对照组)。AML-MRC组男8例,女9例,中位年龄35(17~61)岁;对照组男52例,女33例,中位年龄31(11~60)岁。AML-MRC组、对照组移植后巨细胞病毒、EB病毒、血流感染发生率及造血重建比较差异均无统计学意义(P>0.05),移植后2年总生存率分别为80.8%(95% CI 51.6%~93.4%)、72.5%(95% CI 62.8%~80.1%)(P=0.650),无病生存率分别为79.4%(95% CI 48.8%~92.9%)、65.9%(95% CI 54.3%~75.2%)(P=0.573),累积复发率分别为13.0%(95% CI 1.9%~34.7%)、13.3%(95% CI 7.0%~21.5%)(P=0.623),非复发死亡率分别为6.7%(95% CI 0.3%~27.0%)、20.0%(95% CI 12.0%~29.4%)(P=0.436)。 结论 CR1期AML-MRC与其他类型高危AML患者haplo-HSCT的预后相似。haplo-HSCT是CR1期AML-MRC患者的理想选择。
Collapse
|
115
|
Dou XL, Zhao T, Xu LP, Zhang XH, Wang Y, Chen H, Chen YY, Yan CH, Han W, Wang FR, Wang JZ, Chen Y, Jiang H, Zhu HH, Jia JS, Wang J, Jiang B, Wang DB, Liu KY, Huang XJ, Jiang Q. [Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:969-976. [PMID: 30612396 PMCID: PMC7348229 DOI: 10.3760/cma.j.issn.0253-2727.2018.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
目的 探讨非老年成人初发急性髓系白血病(AML)患者年龄相关的临床特征、早期治疗反应和预后。 方法 回顾性分析2008年1月至2017年12月收治的18~65岁初发AML(非急性早幼粒细胞白血病)连续病例,分析不同年龄组患者初诊时疾病特征、早期治疗反应、复发和生存,以及相关影响因素。 结果 共收集1 097例患者,男性591例(53.9%),中位年龄42岁。随着年龄的增长,患者WBC显著下降(P=0.003),PLT显著上升(P=0.034),骨髓原始细胞比例显著下降(P=0.021)。SWOG危险度在各年龄组的分布差异无统计学意义(P=0.063)。NPM1阳性伴FLT3-ITD阴性的患者比例随年龄增长显著上升(P<0.001)。多因素分析显示,在总人群中,年龄增加是获得形态学无白血病状态(MLFS)(P=0.053)、完全缓解(CR)(P=0.004)和总生存(OS)(P=0.070)的不利影响因素,但在接受标准诱导治疗的患者中,年龄增加仅与CR相关(P=0.075),而与MLFS和OS无关。 结论 非老年初发AML患者的临床、细胞遗传学和分子学特征随年龄变化而不同。在接受标准诱导治疗的患者中,年龄增加与获得MLFS和OS均无显著相关性。
Collapse
|
116
|
Hong Y, Qin YZ, Xu YY, Zhou SH, Wang Y, Xu LP, Zhang XH, Huang XJ, Zhao XS. [Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 38:680-684. [PMID: 28954346 PMCID: PMC7348250 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the clinical significance of monitoring ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia (ALL) after allogeneic stem cell transplantation (allo-HSCT) . Methods: Clinical data of 13 children received allo-HSCT in Peking University Institute of Hematology from May 2009 to March 2016 were retrospectively collected. The ETV6-RUNX1 gene was examined by real-time quantitative polymerase chain reaction (RQ-PCR) . The correlation between its expression level and the disease status was analyzed. Results: Of 13 enrolled ALL cases, the ETV6-RUNX1 expression of 7 patients converted to positive after transplant at a median time of 137 days (range, 28-270 days) . The expression level of the first positive sample was 0.034% (range, 0.004%-0.061%) . The duration from ETV6-RUNX1 positive to hematological relapse was 196 days (range, 28-666 days) . Four patients experienced relapse at a median time of 294 days (range, 104-803 days) after allo-HSCT. The ETV6-RUNX1 expression converted to positive prior to MRD. Patients with positive ETV6-RUNX1 gene expression pre-transplantation would be more likely to relapse. Conclusion: Monitoring ETV6-RUNX1 by RQ-PCR could be used to evaluate MRD status after allo-HSCT. Patients with positive ETV6-RUNX1 after transplant had a poor prognosis.
Collapse
|
117
|
Han TT, Zhao XS, Huang XJ, Zhang XH, Liu KY, Wang Y, Yan CH, Xu LP. [Significance of PCR detection of HHV6 in gastro biopsy on the course of diarrhea in patients with severe diarrhea after allogeneic hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 38:690-694. [PMID: 28954348 PMCID: PMC7348244 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 探讨肠黏膜人疱疹病毒6型(HHV6)检测在异基因造血干细胞移植(allo-HSCT)术后重度腹泻患者中的意义。 方法 回顾性分析2015年2月至2016年8月于北京大学血液病研究所行allo-HSCT后出现重度腹泻并行肠镜检查及肠黏膜活检的患者资料;HHV6、CMV、EBV检测采用RT-PCR方法;肠黏膜病理检查也包括免疫组化方法检测CMV早期抗原、CMV晚期抗原,原位杂交检测EBV。 结果 共有45例患者纳入研究,其中21例(46.7%)肠黏膜活检HHV6阳性,包括男13例,女8例,中位年龄29(14~54)岁;肠黏膜HHV6阳性与阴性组患者血CMV阳性检出率差异无统计学意义(76.2%对87.5%,P>0.05),但EBV血症发生率前者(6/21,28.6%)明显高于后者(1/24,4.2%)(P=0.028);两组患者在腹泻发生的时间、次数及量方面差异无统计学意义(P值均>0.05)。45例患者中44例接受了膦甲酸钠和(或)更昔洛韦抗病毒治疗,抗病毒治疗并没有影响腹泻的进程。 结论 肠黏膜HHV6阳性在allo-HSCT术后重症腹泻患者中发生率高,未发现其对于治疗及预后有临床意义。肠黏膜HHV6阳性并不能证明HHV6在肠道的感染。
Collapse
|
118
|
Hu Y, Chen K, Li YL, He JY, Zhang KS, Liu T, Xu W, Huang XJ, Kong LT, Liu JH. Morphology-tunable WMoO nanowire catalysts for the extremely efficient elimination of tetracycline: kinetics, mechanisms and intermediates. NANOSCALE 2019; 11:1047-1057. [PMID: 30569932 DOI: 10.1039/c8nr08162j] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
The presence of antibiotics in aquatic environments has attracted global concern. The Fenton system is one of the most popular methods for eliminating antibiotics in aquatic environments, but the existing Fenton system is limited due to the potential for secondary pollution, and the narrow pH range (∼3-5). In this study, we report that the bottlenecks for high-strength tetracycline (TC) wastewater treatment under neutral conditions can be tackled well by a class of mixed-valence W/Mo containing oxides (WMoO-x) with tunable morphologies. Triethanolamine was selected as a structure-directing agent to control the morphologies of the catalysts going from ultrathin nanowires (UTNWs) to wire-tangled nanoballs (WTNBs). As a proof of concept, the most efficient catalyst in the batch samples, WMoO-1 ultrathin nanowires, was employed as a model material for TC degradation, in which the coordinatively unsaturated metal atoms with oxygen defects serve as the sites for TC chemisorption and electron transfer. As a result, 91.75% of TC was degraded in 60 min for the initial TC concentration of 400 μM. Furthermore, LC-MS analysis confirmed that the TC could be degraded to nontoxic by-products without benzene rings, and finally mineralized to CO2 and H2O. ICP-MS and cycle experiments showed the good stability and reusability of WMoO-1 UTNWs in the Fenton-like system. The findings of this work provide fresh insights into the design of nanoscale catalyst morphology and reaffirm the versatility of doping in tuning catalyst activity, extending the range of the optimal pH values to neutral conditions. This is significant for the expansion of the heterogeneous Fenton-like family and its application in the field of water treatment.
Collapse
|
119
|
Liu T, Li YL, He JY, Hu Y, Wang CM, Zhang KS, Huang XJ, Kong LT, Liu JH. Porous boron nitride nanoribbons with large width as superior adsorbents for rapid removal of cadmium and copper ions from water. NEW J CHEM 2019. [DOI: 10.1039/c8nj05299a] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Porous boron nitride nanoribbons with large width and their possible mechanism for the removal of heavy metals.
Collapse
|
120
|
Wang Y, Huang XJ. [Advances in haploidentical hematopoietic stem cell transplantation for myelodysplastic syndromes]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 38:348-351. [PMID: 28468102 PMCID: PMC7342714 DOI: 10.3760/cma.j.issn.0253-2727.2017.04.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
121
|
Wang YZ, Lu J, Hao L, Chang Y, He LL, Huang XJ, Liu YR. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 38:272-278. [PMID: 28468086 PMCID: PMC7342730 DOI: 10.3760/cma.j.issn.0253-2727.2017.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
目的 探讨与比较4色和8色荧光抗体组合检测多发性骨髓瘤(MM)患者治疗后微小残留病(MRD)的灵敏度。 方法 建立一组以CD38/CD138对浆细胞进行设门,同时检测胞膜抗原CD45、CD19、CD56、CD117及胞质轻链cKappa、cLambda的8色抗体组合;6组4色抗体组合中,4组以CD38/CD138设门,分别分析CD45/CD19、CD56/CD117、CD19/CD56胞膜抗原(M1-3)和胞质轻链(C组)表达;MC1-2组分别以CD38/SSC和CD138/SSC设门,同时检测CD19或CD45胞膜抗原和胞质轻链。采用以上组合对20名健康志愿者和73例完全缓解后MM患者标本进行检测并进行比较分析。 结果 8色组合识别异常浆细胞(aPCs)和克隆性浆细胞(cPCs)的阳性率均为82.19%,一致率为89.04%(65/73);cPCs中位比例为0.105%,均显示明显的单克隆轻链;敏感度为0.004%。CD38/SSC设门的浆细胞比例明显高于CD38/CD138(P<0.001)和CD138/SSC(P=0.001)设门。4色组合中C-胞质组MRD阳性率最低,仅为65.75%,明显低于8色组合的82.19%(P=0.024);M2-56/117组检测的aPCs比例最低,为0.095%,与其他组相比差异有统计学意义(P=0.014);MC1-CD38和MC2-CD138组,以cPCs作为判断标准时MRD阳性率均高于以aPCs为判断标准(P<0.05),结果一致率分别为68.49%(50/73)和79.45%(58/73)。与8色组合相比,4色组合中MC2-CD138组敏感性、准确性和阴性预测值最高,阳性预测值和特异性也较高;其次是M1-45/19组。 结论 CD38/CD138设门更准确,反映克隆性的胞质轻链检测较胞膜抗原更敏感,胞膜抗原异常表达并不完全代表为cPCs,建议胞膜抗原和胞质轻链同时检测。有条件者建议选用8色组合,4色组合中建议同时采用M1-45/19和MC2-CD138组合。
Collapse
|
122
|
Ren X, Zhao T, Wang J, Zhu HH, Jiang H, Jia JS, Yang SM, Jiang B, Wang DB, Huang XJ, Jiang Q. [Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 38:185-191. [PMID: 28395440 PMCID: PMC7348386 DOI: 10.3760/cma.j.issn.0253-2727.2017.03.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 探讨首次获骨髓无白血病状态时血细胞恢复程度[包括完全缓解(CR,ANC≥1.0× 109/L和PLT≥100×109/L)、PLT未恢复(CRp)、ANC和PLT均未恢复(CRi)]对初治成人急性髓系白血病(AML)患者预后的影响。 方法 回顾2008年1月至2016年2月北京大学人民医院收治的获得骨髓无白血病状态后持续化疗AML(非急性早幼粒细胞白血病)连续病例,分析诊断时疾病特征、诱导化疗方案、首次诱导化疗反应以及骨髓无白血病状态时血细胞计数与预后的关系。 结果 352例患者,男179例(50.9%),中位年龄44(17~65)岁。按美国西南肿瘤组(SWOG)标准分组:低危87例(24.7%),中危171例(48.6%),高危46例(13.1%),未知48例(13.6%)。单体核型16例(4.5%),FLT3-ITD突变阳性41例(11.6%)。首次获骨髓无白血病状态时血细胞恢复程度:CR 299例(84.9%),CRp 26例(7.4%),CRi 27例(7.7%)。存活患者中位随访16(2~94)个月,30个月累积复发(CIR)、无病生存(DFS)和总生存(OS)率分别为47.5%、46.0%和58.6%。多因素分析显示,骨髓无白血病状态时血细胞恢复不良是影响患者CIR、DFS和OS的共同不利因素(HR=1.4,95% CI 1.0~1.9,P=0.037;HR=1.5,95% CI 1.1~2.0,P= 0.003;HR=1.5,95% CI 1.1~2.0,P=0.017)。此外,SWOG分组危险度高和FLT3-ITD突变阳性是影响患者CIR、DFS和OS的共同不利因素;确诊时外周血原始细胞比例高是影响患者DFS的不利因素;年龄大和确诊时骨髓原始细胞比例高是影响患者OS的不利因素。 结论 持续化疗的成人AML患者,首次获骨髓无白血病状态时血细胞恢复程度是影响预后的独立因素。
Collapse
|
123
|
Li G, Su Y, Li YY, Li YX, Guo Z, Huang XJ, Liu JH. Size-tunable Ag nanoparticles sensitized porous ZnO nanobelts: controllably partial cation-exchange synthesis and selective sensing toward acetic acid. NANOTECHNOLOGY 2018; 29:445501. [PMID: 30109994 DOI: 10.1088/1361-6528/aada6e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Porous ZnO nanobelts sensitized with Ag nanoparticles have been prepared via a partial cation-exchange reaction assisted by a thermal oxidation treatment, employing ZnSe·0.5N2H4 nanobelts as precursors. After partially exchanged with Ag+ cations, the belt-like morphology of the precursors is still preserved. Continuously calcined in air, they are in situ transformed into Ag nanoparticles sensitized porous ZnO nanobelts. The size of the Ag nanoparticles can be tuned through manipulating the amount of exchanging Ag+ cations. Considering the porous and belt-like nanostructure, sensing characteristics of ZnO and the catalytic activity of Ag nanoparticles, the gas sensing performances of the as-prepared Ag nanoparticles sensitized porous ZnO nanobelts have been carefully investigated. The results indicate that Ag nanoparticles significantly enhance the sensing performances of porous ZnO nanobelts toward typical volatile organic compounds. Especially, a good selectivity has been demonstrated toward acetic acid gas with a low detection limit less than 1 ppm. Furthermore, they also display a good reproducibility with a short response/recovery time due to the thin, uniform and porous sensing film, which is fabricated with the assembled technique and in situ calcined approach. Finally, their sensing mechanism has been further discussed.
Collapse
|
124
|
Li SS, Zhou WY, Jiang M, Li LN, Sun YF, Guo Z, Liu JH, Huang XJ. Insights into diverse performance for the electroanalysis of Pb(II) on Fe2O3 nanorods and hollow nanocubes: Toward analysis of adsorption sites. Electrochim Acta 2018. [DOI: 10.1016/j.electacta.2018.08.069] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
125
|
Liu J, Jia JS, Gong LZ, Lu SY, Zhu HH, Huang XJ, Jiang H. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 39:734-738. [PMID: 30369183 PMCID: PMC7342258 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/25/2018] [Indexed: 12/31/2022]
Abstract
Objective: To evaluate the clinical efficacy and safety of decitabine in combination with lower-dose CAG regimen (G-CSF, cytarabine and aclarubicin; D-CAG regimen) in the treatment of myelodysplastic syndromes with excess blasts (MDS-EB) and acute myeloid leukemia with myelodysplasia-related changes (AML-MRC), compared to standard CAG regimen. Methods: A total of 42 patients with newly diagnosed MDS-EB and AML-MRC from May 2011 to March 2017 were included in the retrospective study. 21 cases were initially treated with G-CSF for priming, in combination with cytarabine of 10 mg/m(2) q12h for 14 days and aclarubicin of 20 mg/d for 4 days (CAG regimen) and the other 21 cases were initially treated with decitabine of 20 mg/m(2) for 5 days and lower-dose CAG regimen (cytarabine of 10 mg/m(2) q12h for 7 days, aclarubicin of 10 mg/d for 4 days, and G-CSF for priming (D-CAG regimen). After two cycles of induction chemotherapy, the patients who obtained complete remission(CR) received consolidation chemotherapy or hematopoietic stem cell transplantation (HSCT). Results: Among a total of 42 patients, the median age was 52.5 years (18-65 years) and 64.3% of them were male. Baseline characteristics of patients between D-CAG group and CAG group showed no significant differences. The CR for patients in D-CAG group was 81.0% (17/21), compared to 52.4% (11/21) in CAG group after 2 cycles of therapy (χ(2)=3.857, P=0.050). The overall response rate (ORR) for patients in D-CAG group and CAG group was 85.7% (18/21) and 76.2% (15/21) respectively, without significant difference (χ(2)=1.273, P=0.259). By December 2017, the median follow-up of D-CAG group and CAG group was 13(6-32) months and 15(2-36) months respectively. Finally, 10 patients in D-CAG group and 7 patients in CAG group received HSCT respectively. Except patients receiving HSCT, the median leukemia-free survival (LFS) time for patients in D-CAG group and CAG group was 18.0 (95%CI 6.6-29.4) months and 11.0 (95%CI 0-23.9) months respectively. Probabilities of 12 months LFS for D-CAG group and CAG group were (63.6±14.5)% and (50.0±13.4)% respectively, without difference (χ(2)=0.049, P=0.824). Except patients receiving HSCT, there were 2 deaths in D-CAG group and 7 deaths in CAG group respectively. The cumulative probabilities of 12 months OS for non-HSCT patients in D-CAG group and CAG group were (90.9±8.7)% and (61.5±13.5)% respectively, without significant difference (χ(2)=1.840, P=0.175). The incidences of side effects between D-CAG group and CAG group did not show significant differences (P=0.479), and the main side effects included cytopenias, pneumonia, infections of skin and soft tissues, neutropenic patients with fever, liver dysfunction. Conclusion: The decitabine in combination with lower-dose CAG regimen improved CR for patients with MDS-EB and AML-MRC, and was a promising choice.
Collapse
|
126
|
Zhao X, Yu FQ, Huang XJ, Xu BY, Li YL, Zhao XY, Guo HF, Luan B. Azithromycin influences airway remodeling in asthma via the PI3K/Akt/MTOR/HIF-1α/VEGF pathway. J BIOL REG HOMEOS AG 2018; 32:1079-1088. [PMID: 30334401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Asthma is a respiratory disease that affects people of all walks of life, and is a hotspot of continuous research, with significant manpower and resources invested in its study. Airway remodeling is an important associated pathological change, and a mark of the irreversible damage produced by asthma. It involves compositional and functional changes in the cells of the airway walls, leading to reversible structural changes, and complicating treatment. Airway remodeling is mediated by different inflammatory pathways which have been targeted for treatment, with good results. However, given its complexity, systematic study of the pathogenesis of airway remodeling is still needed, and additional targeted therapies are necessary. Macrolide drugs, such as erythromycin, azithromycin, and clarithromycin, have antibacterial effects and also influence the cytokine secretion of macrophages and T-lymphocytes. They have direct effects on a variety of cytokines, inhibiting inflammation and reducing airway reactivity. In this study, we investigated the protective effect of azithromycin on airway remodeling through the phosphoinositol-3 kinase/Akt/mechanistic target of rapamycin kinase/hypoxia-inducible factor 1α (HIF-1α)/vascular endothelial growth factor (VEGF) pathway. We observed that a long course of azithromycin could significantly reduce airway reactivity and ovalbulmin-induced pathological alterations in asthmatic mice. Gene expression analysis confirmed that HIF-1α and VEGF were significantly down-regulated following a long course of azithromycin administration.
Collapse
|
127
|
Chen SH, Li YX, Li PH, Xiao XY, Jiang M, Li SS, Zhou WY, Yang M, Huang XJ, Liu WQ. Electrochemical spectral methods for trace detection of heavy metals: A review. Trends Analyt Chem 2018. [DOI: 10.1016/j.trac.2018.07.005] [Citation(s) in RCA: 44] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
|
128
|
Dou XL, Wang SS, Fang JL, Yu L, Ren X, Huang XJ, Jiang Q. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia]. ZHONGHUA NEI KE ZA ZHI 2018; 57:649-655. [PMID: 30180449 DOI: 10.3760/cma.j.issn.0578-1426.2018.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the incidence and severity of hepatic adverse events (AEs) and identify factors associated with hepatic AEs in patients with chronic myeloid leukemia (CML) in chronic phase (CP) treated with tyrosine kinase inhibitors (TKIs). Methods: Liver biochemistry parameters [including ALT(alanine aminotransferase), AST(aspartate aminotransferase), ALP(alkaline phosphatase), and TBil(total bilirubin)] during the first 6 months on imatinib (Gleevec(®)), dasatinib (Sprycel(®)) or nilotinib (Tasigna(®)) in CML-CP patients were collected and analyzed retrospectively. Results: A total of 436 patients were enrolled in this study, including 271 with imatinib, 58 with dasatinib, and 107 with nilotinib. The incidences of any abnormality of liver injury were 21.8%(59/271), 15.5%(9/58) and 32.7%(35/107) in the imatinib, dasatinib and nilotinib groups, respectively. Most of the hepatic AEs were CTCAE grade 1 or 2 and mild or moderate liver injury except 1.9% of TBil CTCAE grade 3 in the nilotinib group. Multivariate analyses showed nilotinib [OR=2.9(1.3-6.6), P=0.012; OR=4.4(1.2-15.6), P=0.023] and male gender [OR=2.3(1.4-3.9), P=0.002; OR=3.0(1.2-7.6), P=0.018] were significantly associated with moderate liver impairment. Conclusions: TKIs including imatinib, dasatinib and nilotinib were well tolerated with mild to moderate hepatic AEs in CML-CP patients. Nilotinib and male sex were associated with occurrence of liver biochemistry abnormalities and moderate hepatic injury.
Collapse
|
129
|
Liu Y, Huang XJ, Jiang H, Zhu Y, Zhou XH, Gong LZ. [The 464th case: sudden convulsion and coma in a patient with acute leukemia]. ZHONGHUA NEI KE ZA ZHI 2018; 57:539-541. [PMID: 29996279 DOI: 10.3760/cma.j.issn.0578-1426.2018.07.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
A 46-year-old female patient was diagnosed as mixed phenotype acute leukemia with chief complaints of intermittent gingival swelling and bleeding for 1 week. The induction chemotherapy was not effective. During the second course chemotherapy, the patient had sudden convulsion and coma. She was transferred to the intensive care unit with worsened condition after transient improvement. Her final diagnosis was secondary adrenocortical insufficiency, adrenal crisis, intractable hyponatremia and cerebral edema.
Collapse
|
130
|
Guo Z, Su Y, Li YX, Li G, Huang XJ. Porous Single-Crystalline CdSe Nanobelts: Cation-Exchange Synthesis and Highly Selective Photoelectric Sensing toward Cu2+. Chemistry 2018; 24:9877-9883. [DOI: 10.1002/chem.201801215] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Indexed: 02/02/2023]
|
131
|
Li L, Wang Y, Yan CH, Huang XJ. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients]. ZHONGHUA NEI KE ZA ZHI 2018. [PMID: 29518863 DOI: 10.3760/cma.j.issn.0578-1426.2018.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the threshold of cytomegalovirus (CMV) DNAemia for preemptive antiviral therapy in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Methods: Viral load between 1×10(3) copies/ml and 5×10(3) copies/ml was defined as low viral load by real time Q-PCR. Clinical data and outcome were collected. Results: A total of 95 allo-HSCT recipients with low viral load from September 2014 to February 2015 were recruited in this study. The control group included 37 patients who received preemptive initial antiviral therapy. The other 58 patients didn't received antiviral treatment after positive viremia was confirmed. During monitoring, CMV viremia was cleared spontaneously in 17 patients of study group. Among 41 patients with continuous positive viremia in study group, 26 patients received antiviral therapy after second positivity including 18 with viral load >5×10(3) copies/ml, 2 with fever but still low viral load, 2 with hemorrhagic cystitis and low viral load, 4 with continuous low viral load. Eleven patients received antiviral therapy after the third positivity including 5 with viral load >5×10(3) copies/ml, 1 low viral load patient with fever and diarrhea, 5 with continuous low viral load. Only 4 patients received antiviral therapy after the fourth positivity of >5×10(3) copies/ml. In the study group, 35 cases received ganciclovir and 6 cases received foscarnet. The incidence of neutropenia did not differ significantly between study and control groups [minimum of neutrophil count: (1.63±0.41)×10(9)/L vs. (1.58±0.36)×10(9)/L]. The proportion of viral load greater than 5×10(3) copies/ml in the first week was comparable in two groups. Successful viral clearance rate was not statistically different (P=0.87). Of all 95 patients, no CMV diseases developed, neither did patient die of CMV infection. Conclusions: Spontaneous clearance of viremia occurs in some patients receiving allo-HSCT with low CMV viral load. Delayed antiviral treatment of continuous positive viremia does not prolong the whole treatment duration, neither contributes to the progression of CMV diseases.
Collapse
|
132
|
Zhao T, Zhu HH, Wang J, Jia JS, Yang SM, Jiang H, Lu J, Chen H, Xu LP, Zhang XH, Jiang B, Ruan GR, Wang DB, Huang XJ, Jiang Q. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 38:10-16. [PMID: 28219218 PMCID: PMC7348393 DOI: 10.3760/cma.j.issn.0253-2727.2017.01.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
目的 探讨NPM1突变阳性急性髓系白血病(AML)患者化疗后早期微小残留病(MRD)水平与预后的关系。 方法 回顾性分析137例初治成人伴NPM1基因主要突变(A、B、D突变)AML患者的治疗结果,以及化疗后早期时间点MRD(NPM1突变转录本)水平对预后的影响。 结果 在137例患者中,男67例(48.9%),中位年龄49(16~67)岁,染色体正常核型107例(78.1%),FLT3-ITD突变阳性57例(41.6%),初诊时NPM1基因突变转录本中位水平84.1%(4.1%~509.9%)。在134例可评估的患者中,115例(85.8%)最终获完全缓解(CR)。多因素分析显示,WBC<100×109/L(OR=0.3,95% CI 0.1~0.9,P=0.027)和初始诱导治疗为“IA10”方案(OR=0.3,95% CI 0.1~0.8,P=0.015)是获得CR的有利因素。在108例可评估的CR患者中,存活患者中位随访24(2~91)个月,3年无病生存(DFS)和总生存(OS)率分别为48.0%和63.9%。多因素分析显示,FLT3-ITD突变阳性(HR=3.2,95% CI 1.6~6.7,P=0.002)、巩固治疗2个疗程后MRD高水平(NPM1突变转录本水平较治疗前下降<3个对数级,HR=23.2,95% CI 7.0~76.6,P<0.001)、未接受异基因造血干细胞移植(allo-HSCT)(HR=2.6,95% CI 1.0~6.6,P=0.045)是影响患者DFS的不利因素;MRD在首次获得CR时高水平(NPM1突变转录本水平下降<2个对数级,HR=2.5,95% CI 1.0~6.1,P=0.040)和巩固治疗2个疗程后高水平(HR=4.5,95% CI 2.0~10.3,P<0.001)是影响患者OS的不利因素。进一步分析78例接受化疗(或自体移植)的CR患者,3年DFS和OS率分别为39.7%和59.1%,FLT3-ITD突变阳性和巩固治疗2个疗程后MRD高水平是独立影响患者DFS(HR=3.5,95% CI 1.6~7.6,P=0.002和HR=8.9,95% CI 3.8~20.7,P<0.001)和OS(HR=2.7,95% CI 1.1~6.9,P=0.036和HR=3.1,95% CI 1.2~8.0,P=0.021)的共同不利因素,此外,首次获得CR时MRD高水平(HR=3.1,95% CI 1.2~8.0,P=0.022)也是影响患者OS的不利因素。 结论 在NPM1突变阳性AML患者中,伴有FLT3-ITD突变和化疗后早期MRD高水平预示不良预后。
Collapse
|
133
|
Zhou WY, Li SS, Song JY, Jiang M, Jiang TJ, Liu JY, Liu JH, Huang XJ. High Electrochemical Sensitivity of TiO 2- x Nanosheets and an Electron-Induced Mutual Interference Effect toward Heavy Metal Ions Demonstrated Using X-ray Absorption Fine Structure Spectra. Anal Chem 2018. [PMID: 29542323 DOI: 10.1021/acs.analchem.7b02315] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Mutual interference is a severe issue that occurs during the electrochemical detection of heavy metal ions. This limitation presents a notable drawback for its high sensitivity to specific targets. Here, we present a high electrochemical sensitivity of ∼237.1 μA cm-2 μM-1 toward copper(II) [Cu(II)] based on oxygen-deficient titanium dioxide (TiO2- x) nanosheets. We fully demonstrated an atomic-level relationship between electrochemical behaviors and the key factors, including the high-energy (001) facet percentage, oxygen vacancy concentration, surface -OH content, and charge carrier density, is fully demonstrated. These four factors were quantified using Raman, electron spin resonance, X-ray photoelectron spectroscopy spectra, and Mott-Schottky plots. In the mutual interference investigation, we selected cadmium(II) [Cd(II)] as the target ion because of the significant difference in its stripping potential (∼700 mV). The results show that the Cd(II) can enhance the sensitivity of TiO2- x nanosheets toward Cu(II), exhibiting an electron-induced mutual interference effect, as demonstrated by X-ray absorption fine structure spectra.
Collapse
|
134
|
Li SS, Zhou WY, Jiang M, Guo Z, Liu JH, Zhang L, Huang XJ. Surface Fe(II)/Fe(III) Cycle Promoted Ultra-Highly Sensitive Electrochemical Sensing of Arsenic(III) with Dumbbell-Like Au/Fe3O4 Nanoparticles. Anal Chem 2018; 90:4569-4577. [DOI: 10.1021/acs.analchem.7b04981] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
135
|
Wang WJ, Sun YQ, Tang FF, Han TT, Mo XD, Wang JZ, Zhang XH, Huang XJ, Xu LP. [Outcomes of alternative donor allogeneic hematopoietic stem cell transplantation for Fanconi anemia: a five cases report]. ZHONGHUA NEI KE ZA ZHI 2018; 57:54-56. [PMID: 29325312 DOI: 10.3760/cma.j.issn.0578-1426.2018.01.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Five patients with Fanconi anemia who received hematopoietic cell transplantation were retrospectively analyzed. The conditioning regimens included fludarabine, cyclophosphamide and anti-thymocyte globulin. Two patients received both bone marrow and peripheral blood stem cells as the source of stem cell grafts from haploidentical matched related donors, while the others received peripheral blood stem cells from unrelated donors. All patients tolerated well and reached hematopoietic reconstitution. One patient died of intracranial infection. During follow-up, 4 patients survived independent of transfusion with full donor chimerism.
Collapse
|
136
|
Ren X, Zhao T, Wang J, Zhu HH, Jiang H, Jia JS, Yang SM, Jiang B, Wang DB, Huang XJ, Jiang Q. [Outcomes of adult patients with de novo acute myeloid leukemia received idarubicin plus cytarabine regimen as induction chemotherapy]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2018; 39:15-21. [PMID: 29551027 PMCID: PMC7343116 DOI: 10.3760/cma.j.issn.0253-2727.2018.01.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/25/2017] [Indexed: 11/27/2022]
Abstract
Objective: To explore outcomes in adult with de novo acute myeloid leukemia (AML) received IA10 (10 mg/m(2) d1-3 idarubicin plus cytarabine 100 mg/m(2) d1-7) regimen as induction chemotherapy. Methods: From January 2008 to February 2016, data of consecutive newly-diagnosed AML (non-M(3)) adults treated with IA10 who achieved morphologic leukemia-free state (MLFS) but not accepted allogeneic hematopoietic stem cell transplantation (allo-HSCT) were assessed retrospectively. Results: A total of 198 patients were included in this study with 96 (48.5%) male and a median age of 42 years old (range, 18-62 years old). Using the SWOG cytogenetic classification, 45 (22.7%), 104 (52.5%), 24 (12.1%) and 25 (12.6%) patients belonged to favorable, intermediate, unfavorable and unknown categories, respectively. 6 (3.0%) patients had monosomal karyotype, and 28 (14.1%) positive FLT3-ITD mutation. A complete remission (CR, defined as MLFS with ANC ≥ 1×10(9)/L and PLT ≥ 100×10(9)/L) achieved in 168 (84.8%) patients, a CRp (defined as MLFS with incomplete PLT recovery) in 16 (8.1%) and a CRi (defined as MLFS with incomplete ANC and PLT recovery) in 14 (7.1%). With a median follow-up period of 15 months (range, 1 to 70 months) in survivors, the probabilities of cumulative incident of relapse (CIR), disease free survival (DFS) and overall survival (OS) rates at 2-year were 45.2%, 46.9% and 62.9%, respectively; the median durations of relapse, DFS and OS were 34, 20 and 37 months respectively. At the time of achieving first MLFS, multivariate analyses showed that positive FLT3-ITD mutation and CRi were common adverse factors affecting CIR, DFS and OS; unfavorable-risk of SWOG criteria was an adverse factor affecting CIR and DFS; monosomal karyotype was associated with shorter OS. After first consolidation therapy, FLT3-ITD mutation positive and unfavorable-risk of SWOG criteria had negatively impact on CIR, DFS and OS; peripheral blasts ≥ 0.50 and positive MRD (defined as RQ-PCR WT1 mRNA ≥ 0.6% or any level of abnormal blast population detected by flow cytometry) after first consolidation therapy were common adverse factors affecting CIR and DFS; CRi was an adverse factor affecting DFS and OS. Conclusions: In adult with de novo AML received IA10 regimen as induction regimen, unfavorable molecular markers or cytogenetics at diagnosis and CRi independently predicted poor outcome. In addition, a higher percentage of peripheral blasts, monosomal karyotype and positive MRD after first consolidation therapy had negatively impact on outcomes.
Collapse
|
137
|
Zhou WY, Li SS, Xiao XY, Chen SH, Liu JH, Huang XJ. Defect- and phase-engineering of Mn-mediated MoS2 nanosheets for ultrahigh electrochemical sensing of heavy metal ions: chemical interaction-driven in situ catalytic redox reactions. Chem Commun (Camb) 2018; 54:9329-9332. [DOI: 10.1039/c8cc04575e] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
An ultrasensitive electrochemical detection of heavy metal ions is achieved via defect- and phase-engineering of Mn-mediated MoS2 nanosheets.
Collapse
|
138
|
Li SS, Zhou WY, Li YX, Jiang M, Guo Z, Liu JH, Huang XJ. Noble-Metal-Free Co0.6Fe2.4O4 Nanocubes Self-Assembly Monolayer for Highly Sensitive Electrochemical Detection of As(III) Based on Surface Defects. Anal Chem 2017; 90:1263-1272. [DOI: 10.1021/acs.analchem.7b04025] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
139
|
Duan WB, Gong LZ, Jia JS, Zhu HH, Zhao XS, Jiang Q, Zhao T, Wang J, Qin YZ, Huang XJ, Jiang H. [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive]. BEIJING DA XUE XUE BAO. YI XUE BAN = JOURNAL OF PEKING UNIVERSITY. HEALTH SCIENCES 2017; 49:990-995. [PMID: 29263470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE To investigate the clinical biological characteristics of EVI1 positive acute myeloid leukemia (AML) and its effect on early chemotherapy. METHODS The clinical and biological cha-racteristics of 33 AML patients with EVI1 positive were retrospectively analyzed in 361 AML patients who were diagnosed and treated in our institute from March 2015 to July 2016, and the clinical and biological features, and rates of the induced remission were compared between the intermediate risk and poor risk with EVI1 positive AML, moreover, the influential factors on complete remission (CR) were analyzed. The expression of EVI1/ABL was tested in 32 healthy donors to confirm the abnormal threshold of EVI1 expression. RESULTS The definition of EVI1 positive was that the quantitative expression of EVI1/ABL was more than 8.0%. The 33 AML patients with EVI1 positive were found in 361 newly diagnosed AML patients, in which the female and male patients were 17 and 16 respectively, the median age was 45 (18-67) years, with a median follow-up of 6.6 (0.7-13.2) months. Intermediate karyotype was found in 17 patients(including 9 patients with normal karyotypes,1 patient with +8);unfavorable karyotype was found in 14 patients [including 7 patients with -7/7q-,4 patients with t (v;11q23),3 patients with inv(3)/t(3;3), and 2 patients without mitotic figures]. The rate of CR in the first induction chemotherapy was 42.4%, and the rate of total CR was 60.6%. According to the NCCN, 16 intermediate risk patients and poor risk patients were divided, without favorable risk patients. The rate of CR in the first induction chemotherapy were 68.8% and 17.6% (P=0.005) in the intermediate risk and poor risk respectively, that of total CR were 81.3% and 41.2%(P=0.032), and the rates of relapse were 7.7% and 14.3%.Univariable analysis revealed that unfavorable karyotype could affect the rate of CR in the first reduction chemotherapy and that of total CR (P=0.004, 0.029). The poor risk patients had higher mortality (41.2% vs. 6.3%, P=0.039) and lower overall survival (OS)(P=0.012). CONCLUSION EVI1 may be not an independent prognostic factor for the AML patients considering the appea-rance in the intermediate and poor risk patients. It predicts poor outcome in the EVI1 positive AML patients who have unfavorable karyocytes, such as -7/7q-, t(v;11q23), and inv(3)/t(3;3), and also a low rate of both CR in the first induction chemotherapy and total CR. It also has a low rate of long-term survival and high mortality in the AML patients with EVI1 positive, who may benefit from allogeneic bone marrow transplantation as soon as possible.
Collapse
|
140
|
Chen YY, Luo XY, Zhao XS, Jiang ZH, Chen Y, Chen H, Mo XD, Han W, Wang FR, Wang JZ, Yan CH, Sun YQ, Zhang YY, Han TT, Tang FF, Fu HX, Zhang S, Wang Y, Xu LP, Zhang XH, Liu KY, Huang XJ. [Clinical value of PCR for viral detection of bronchoalveolar lavage fluid in the diagnosis and treatment of pneumonia after allogeneic hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:934-939. [PMID: 29224314 PMCID: PMC7342784 DOI: 10.3760/cma.j.issn.0253-2727.2017.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Indexed: 11/05/2022]
Abstract
Objective: To analyze the clinical value of real-time PCR for virus detection in the diagnosis and treatment of patients after allo-HSCT who had no infection evidence of pneumonia using routine pathogen detection panel. Methods: The clinical data of 71 episodes with acute lung injury from May 2015 to March 2017 after allo-HSCT in hematology department of Peking University People's Hospital (PKUPH) were retrospectively analyzed. PCR for virus detection and other routine pathogen detection tests were performed on bronchoalveolar lavage fluid (BALF) samples. Results: Among 71 episodes with acute lung injury, a total of 15 patients were diagnosed as lower respiratory tract disease merely associated with virus (detection rate of 21.13%) , 19 episodes were absent of lower respiratory tract infection. The median time from allo-HSCT to the occurrence of lung injury were 176 (49-1 376) d and 196 (57-457) d respectively (z=-0.191, P=0.864) . There were no statistical differences for baseline characteristics and clinical features between two groups. The 100-day attributable mortalities were 13.3% (2/15) and 26.3% (5/19) (χ(2)=0.864, P=0.426) . Patients with low-dose steroids treatment had favorable outcome than those with high-dose steroids treatment (the dose of methylprednisolone ≥250 mg/d as standard) [4.2% (1/24) vs 60.0% (6/10) ]. In patients with detectable virus in BALF, 2 patients died with early high-dose steroids treatment, while 11 patients survived with no steroids treatment or late application. Conclusions: Virus infection should be considered in post-HSCT pneumonia patient with negative result using routine pathogen detection panel. Expanding virus detection panel by PCR in BALF could increase diagnostic precision and might be instructive to treatment.
Collapse
|
141
|
Ren X, Zhao T, Wang J, Zhu HH, Jiang H, Jia JS, Yang SM, Jiang B, Wang DB, Huang XJ, Jiang Q. [Factors associated with early treatment response in adults with acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:869-875. [PMID: 29166740 PMCID: PMC7364970 DOI: 10.3760/cma.j.issn.0253-2727.2017.10.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 11/20/2016] [Indexed: 11/05/2022]
Abstract
Objective: To explore the factors influencing early treatment responses in adult with de novo acute myeloid leukemia (AML) . Methods: Data of consecutive newly-diagnosed AML (non-acute promyelocytic leukemia) adults were analyzed retrospectively. To assess the impact of clinical characteristics at diagnosis and induction regimen on achieving morphologic leukemia-free state (MLFS) , blood counts and minimal residual leukemia (MRD, positive MRD defined as RQ-PCR WT1 mRNA ≥0.6% and/or any level of abnormal blast population detected by flow cytometry) at the time of achieving MLFS. Results: 739 patients were included in this study. 406 (54.9%) patients were male, with a median age of 42 years (range, 18-65 years) . In the 721 evaluable patients, MLFS was achieved in 477 (66.2%) patients after the first induction regimen and 592 (82.1%) within two cycles. A total of 634 patients (87.9%) achieved MLFS, including 534 (84.2%) achieving a complete remission (CR, defined as MLFS with ANC ≥ 1×10(9)/L and PLT ≥ 100×10(9)/L) , 100 (15.8%) achieving a CRi (defined as MLFS with incomplete ANC or PLT recovery) , respectively. 260 (45.9%) patients of 566 (89.3%) who detected MRD at the time of achieving MLFS had positive MRD. Multivariate analyses showed that female gender, favorable-risk of SWOG criteria, IA10 and HAA/HAD as induction regimen were factors associated with achieving early MLFS. In addition, low bone marrow blasts, HGB ≥ 80 g/L, PLT counts<30×10(9)/L and mutated NPM1 without FLT3-ITD were factors associated with achieving MLFS after the first induction regimen; Negative FLT3-ITD mutation was factor associated with achieving MLFS within two cycles. PLT counts ≥30×10(9)/L and IA10, IA8 or HAA/HAD as induction chemotherapy were factors associated with achieving CR. Female gender, favorable-risk of SWOG criteria, FLT3-ITD mutation negative, mutated NPM1 without FLT3-ITD were factors associated with negative MRD. Conclusions: Female gender, favorable molecular markers or cytogenetics, and standard-dose induction regimen were key factors associated with higher probability of early and deep responses in adults with AML.
Collapse
|
142
|
Li SS, Jiang M, Jiang TJ, Liu JH, Guo Z, Huang XJ. Competitive adsorption behavior toward metal ions on nano-Fe/Mg/Ni ternary layered double hydroxide proved by XPS: Evidence of selective and sensitive detection of Pb(II). JOURNAL OF HAZARDOUS MATERIALS 2017; 338:1-10. [PMID: 28531655 DOI: 10.1016/j.jhazmat.2017.05.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2017] [Revised: 05/07/2017] [Accepted: 05/10/2017] [Indexed: 05/26/2023]
Abstract
Hypersensitive and highly selective nanomaterials for the measurement of heavy metal ions (HMIs) hold a key to electro-analysis. Various works improved the results of analysis but without scientific understanding. Herein, Fe/Mg/Ni-layered double hydroxide (LDH) has been successfully prepared and its electrochemical behavior for Pb(II) detection is also studied using square wave anodic stripping voltammetry (SWASV). The well performance of electrochemistry suggest that the modification with Fe/Mg/Ni-LDH significantly promotes the selectivity and sensitivity toward Pb(II). The sensitivity on Fe/Mg/Ni-LDH modified glassy carbon electrode (GCE) is 68.1μAμM-1 over the range from 0.03 to 1.0μM under the optimized conditions. Otherwise, the selectivity, anti-interference, stability measurements and practical implications of Fe/Mg/Ni-LDH modified GCE are also performed. What,s more, a reasonable mechanism of detection for Pb(II) including selectivity and sensitivity is proposed based on adsorption and characterized using XPS and XRD. These findings provide a potentially excellent material to improve the sensitivity and selectivity for toxic metal ions as well as a deep understanding of detection.
Collapse
|
143
|
Xu LP, Huang XJ. [How I treat acute graft versus host disease]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:649-655. [PMID: 28954341 PMCID: PMC7348246 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Indexed: 11/23/2022]
|
144
|
Zheng FM, Fu HX, Han TT, Wang FR, Wang JZ, Chen Y, Yan CH, Zhang YY, Han W, Chen YY, Chen H, Wang Y, Zhang XH, Liu KY, Huang XJ, Xu LP. [Comparison of clinical features of hemorrhagic cystitis after haploidentical and matched sibling donor allogeneic hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:656-661. [PMID: 28954342 PMCID: PMC7348249 DOI: 10.3760/cma.j.issn.0253-2727.2017.08.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Indexed: 01/09/2023]
Abstract
Objective: To compare incidence and clinical features of hemorrhage cystitis (HC) after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (HSCT) and matched sibling donor (MSD) HSCT. Methods: Medical records of 609 (including 406 HID-HSCT and 203 MSD-HSCT cases) hematologic malignancies patients treated with HSCT undergoing myeloablative conditioning regimen from January 2011 to December 2012 were analyzed retrospectively. Results: HC occurred 183 in HID and 17 ones in MSD respectively. The cumulative incidence of HC in HID group was higher than in MSD group[ (45.6±2.5) % vs (8.5±2.0) %, χ(2)=77.331, P<0.001], and the cumulative incidence of severe HC (grade 3-4) in HID cases was also higher than in MSD ones[ (11.2±1.9) % vs (2.1±1.1) %, χ(2)=12.883, P<0.001]. All HCs were occurred within 180 days in both groups. The median time to onset in two groups were 27 days after HSCT (range 0-177 days) and 29 days after HSCT (range 6-72 days) respectively (P=0.766) . The median duration of HC in two groups were 21 days (range 3-157 days) and 13 days (range 5-67 days) , respectively (P=0.182) . The total efficiency of treatment in two groups were 69.9% and 70.6% respectively (χ(2)=0.003, P=1.000) . Conclusion: The cumulative incidences of HC and severe HC were higher in HID cases than in MSD ones. The median time to onset and median duration of HC and therapeutic outcome between HID and MSD were comparable.
Collapse
|
145
|
Ren X, Zhao T, Wang J, Zhu HH, Jiang H, Jia JS, Yang SM, Jiang B, Wang DB, Huang XJ, Jiang Q. [Minimal residual disease level predicts outcomes in the non-favorable risk patients with acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:578-585. [PMID: 28810324 PMCID: PMC7342285 DOI: 10.3760/cma.j.issn.0253-2727.2017.07.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Indexed: 11/05/2022]
Abstract
Objective: To explore impact of minimal residual leukemia (MRD) on outcomes in the non-favorable risk adults with de novo acute myeloid leukemia (AML) . Methods: From January 2008 to February 2016, data of consecutive newly-diagnosed non-favorable risk adults with AML (non-APL) according to SWOG criteria who achieved morphologic leukemia-free state (MLFS) and received continuous chemotherapy were assessed retrospectively. Results: 292 AML patients were enrolled, 150 (51.4%) were male. Median age was 46 years (range, 18-65 years) . Using the SWOG cytogenetic classification, 186 (63.7%) , 49 (16.8%) and 57 (19.5%) patients belonged to intermediate, unfavorable and unknown categories, respectively. With a median follow-up period of 15 months (range, 1 to 94 months) in survivors, the probabilities of cumulative rates of relapse (CIR) , disease free survival (DFS) and overall survival (OS) at 2-years were 51.6%, 42.6% and 60.0%, respectively. Multivariate analyses showed that MRD positive (defined as Q-PCR WT1 mRNA ≥0.6% or any level of abnormal blast population detected by flow cytometry) after achieving MLFS and PLT<100×10(9)/L were common adverse factors affecting CIR and DFS. In addition, positive FLT3-ITD mutation and CRp/CRi had negatively impact on CIR, DFS and OS. Monosomal karyotype was adverse factors affecting CIR and OS. Age ≥44 years and unfavorable-risk of SWOG criteria were associated with shorter DFS. Conclusions: MRD level after achieving MLFS had prognostic significance on outcomes in non-favorable adults with AML who received continuous chemotherapy after achieving MLFS.
Collapse
|
146
|
Wang GM, Yang GZ, Huang ZX, Zhong YP, Jin FY, Liao AJ, Wang XM, Fu ZZ, Liu H, Li XL, Zhou JF, Zhang X, Hu Y, Meng FY, Huang XJ, Chen WM, Lu J. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma]. ZHONGHUA NEI KE ZA ZHI 2017; 56:500-506. [PMID: 28693058 DOI: 10.3760/cma.j.issn.0578-1426.2017.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Objective: To evaluate the efficacy and safety of lenalidomide in a real-world clinical practice in Chinese patients with multiple myeloma (MM). Methods: It was a prospective, multi-center, observational study. A total of 165 consecutive patients with MM treated with lenalidomide-based regimens were enrolled in 12 hospitals from June 2013 to November 2015. Relevant information was recorded, such as baseline clinical data, cytogenetic abnormalities, treatment regimens, and duration of treatment, safety, and survival. Results: (1)There were 126 relapsed and refractory MM (RRMM) patients, 25 newly diagnosed patients and 19 maintenance patients. The evaluable RRMM patients accounted for 120 cases, among which 74 cases(61.7%) reached the partial response (PR) or above, and a very good partial response (VGPR) in 16 patients (13.3%), a complete response (CR) in 14 cases (11.7%), a strictly complete response (sCR) in 4 cases (3.3%). Thus, a VGPR or above in 34 patients accounted for 28.3%. (2)The median follow-up was 13 months, the median time to progression 12 months. The median survival after receiving lenalidomide was 19 months, and the median overall survival (OS) was 62 months. (3) The univariate analysis in 120 RRMM patients suggested that prognostic factors for significant improvement in PFS included normal karyotype, international staging system (ISS) Ⅰ-Ⅱ, t(4; 14) negative (detected by fluorescence in situ hybridization), non-bortezomib resistance and response to previous regimens. As to OS, non-bortezomib resistance, response to previous regimens and non-primary refractoriness were positive factors. Multivariate analysis showed that the response to previous regimens (PR or better) was an independent good prognostic factor for progress-free survival(PFS), non-bortezomib resistance and non-primary refractoriness for OS. (4) Grade 3 or 4 adverse events that occurred in more than 10% of all enrolled patients were neutropenia (12.7%), leukocytosis(11.5%) and thrombocytopenia (12.7%). Owing to intolerance of toxic side effects, 7 cases withdrew lenalidomide. Conclusions: No matter what combination, regimens containing lenalidomide are effective to RRMM patients with overall response rate 61.7%, a time to progression 12 months and an overall survival 62 months.The toxicity is quite tolerable and manageable. In addition, the response to previous treatment (reached PR or above) is the independent good prognostic factor for PFS, non-bortezomib resistance and non-primary refractoriness for OS. Clinical trail registration: Clinicaltrials.gov, NCT01947309.
Collapse
|
147
|
Shi HX, Qin YZ, Lai YY, Huang XJ, Jiang Q. [A comparison of efficacy and safety between Chinese generic imatinib versus branded imatinib in patients with newly-diagnosed chronic myeloid leukemia in the chronic phase: a single-center prospective cohort study]. ZHONGHUA NEI KE ZA ZHI 2017; 55:922-926. [PMID: 27916045 DOI: 10.3760/cma.j.issn.0578-1426.2016.12.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To compare the efficacy and safety between Chinese generic imatinib (Xinwei®, Jiansu Hansoh Pharmaceutical Group Co., Ltd.) versus branded imatinib (Glivec®, Novartis) in patients with newly-diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Methods: Patients with newly diagnosed CML-CP were enrolled and assigned to receive either Xinwei or Glivec at an initial dose of 400 mg/d according to patients' financial capability. The efficacy and adverse effects were evaluated. Results: From January 2014 to September 2015, 145 eligible patients were assigned to Xinwei (n=89) or Glivec (n=56) group. All patients were treated and followed up at least 3 months. At 3 months, the complete response rates were 95.5%(85/89) and 100%(56/56), major cytogenetic response rates were 74.2%(66/89) and 80.4%(45/56), and the proportions of achieving BCR-ALBIS≤10% were 76.1%(67/88) and 82.1%(46/56) in Xinwei and Glivec groups respectively (all P>0.05). With a median follow-up of 12 months, 2 patients in each group progressed to accelerate or blast phase. Hematologic and non-hematologic side effects were similar between the 2 groups. Conclusions: Early hematological, cytogenetic and molecular responses between Xinwei and Glivec are comparable in newly-diagnosed CML-CP patients. The progression rate and side effects are also similar between the 2 groups.
Collapse
|
148
|
Jiang TJ, Yang M, Li SS, Ma MJ, Zhao NJ, Guo Z, Liu JH, Huang XJ. In Situ Underwater Laser-Induced Breakdown Spectroscopy Analysis for Trace Cr(VI) in Aqueous Solution Supported by Electrosorption Enrichment and a Gas-Assisted Localized Liquid Discharge Apparatus. Anal Chem 2017; 89:5557-5564. [DOI: 10.1021/acs.analchem.7b00629] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
149
|
Cheng YF, Huang XJ. [Paraplegia after hematopoietic stem cell transplantation]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2017; 38:357-360. [PMID: 28468104 PMCID: PMC7342721 DOI: 10.3760/cma.j.issn.0253-2727.2017.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
150
|
Zhou WY, Liu JY, Song JY, Li JJ, Liu JH, Huang XJ. Surface-Electronic-State-Modulated, Single-Crystalline (001) TiO2 Nanosheets for Sensitive Electrochemical Sensing of Heavy-Metal Ions. Anal Chem 2017; 89:3386-3394. [DOI: 10.1021/acs.analchem.6b04023] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|